Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Summary as of Jun 27, 2018

June 27, 2018 - By Sarah North

Regulus Therapeutics Inc. (NASDAQ:RGLS) Corporate Logo
During Q1 2018 the big money sentiment decreased to 1.11. That’s change of 0.05, from 2017Q4’s 1.16. 8 investors sold all, 10 reduced holdings as Regulus Therapeutics Inc. ratio dropped. 11 rose stakes while 9 funds took stakes. Funds hold 50.71 million shares thus 4.62% less from 2017Q4’s 53.17 million shares.
Natl Bank Of New York Mellon reported 0% stake. Manufacturers Life Ins Co The holds 0% of its capital in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 6,057 shs. The Kansas-based Mariner Limited Liability Com has invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Dowling Yahnke Limited Com holds 0% or 12,000 shs in its capital. Bancorporation Of Montreal Can holds 0% or 4,500 shs. Art Advisors Limited Liability Company accumulated 169,416 shs. Deutsche Commercial Bank Ag holds 98 shs. 18,963 are held by Two Sigma Securities Llc. Barclays Public Limited Liability invested in 91 shs or 0% of the stock. Drw Ltd Com has 135,000 shs for 0.01% of their capital. Rhenman & Prns Asset Ab holds 492,878 shs. Fmr Ltd Liability Com holds 0% or 15.59 million shs in its capital. 737,995 were accumulated by Point72 Asset Mngmt Ltd Partnership. Northern Tru Corporation holds 0% or 187,492 shs in its capital. 1.00 million are held by Ascend Ltd Limited Liability Company.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Total analysts of 5 have positions in Regulus Therapeutics (NASDAQ:RGLS) as follows: 2 rated it a “Buy”, 0 with “Sell” and 3 with “Hold”. The positive are 40%. Since January 5, 2018 according to StockzIntelligence Inc Regulus Therapeutics has 7 analyst reports. On Thursday, March 8 the firm has “Market Perform” rating by BMO Capital Markets given. The stock rating was initiated by FBR Capital with “Hold” on Tuesday, March 27. On Thursday, February 8 the stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Buy” rating given by Wedbush. In Monday, March 12 report Wedbush maintained it with “Buy” rating and $3.0 target. On Thursday, May 17 the firm has “Buy” rating given by Wedbush. Listed here are Regulus Therapeutics Inc. (NASDAQ:RGLS) PTs and latest ratings.

17/05/2018 Broker: Wedbush Rating: Buy New Target: $3.0000 Maintain
28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $1 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $1.0000 Initiate
12/03/2018 Broker: Wedbush Rating: Buy New Target: $3.0 Maintain
08/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $1 New Target: $1.37 Maintain
08/02/2018 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
05/01/2018 Broker: Leerink Swann Rating: Outperform New Target: $2 Initiates Coverage On

The stock 0.60% or $0 during the last trading session, hitting $0.66.Since June 27, 2017 it’s 45.33% down thus downtrending. The stock underperformed the S&P 500 by 57.90%.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States.The firm is worth $68.85 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.Last it reported negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

There’s an important Regulus Therapeutics Inc. (NASDAQ:RGLS) news brought out by Nasdaq.com. It’s a report titled: “New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus …” on June 12, 2018.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: